Skip to main content

Afamelanotide vs Melanotan II

Both Afamelanotide and Melanotan II are used for skin. Here's how their evidence, dosing, and regulatory status actually compare.

Afamelanotide

Evidence A

Afamelanotide (Scenesse)

An FDA-approved selective MC1R agonist used to increase eumelanin density in erythropoietic protoporphyria patients. Off-label cosmetic tanning use is widespread internationally.

View full Afamelanotide profile →

Melanotan II

Evidence C+

Melanotan II (MT-II)

A non-selective melanocortin agonist (MC1R/MC3R/MC4R) that produces tanning and erection effects. Significant safety concerns including melanoma case reports.

View full Melanotan II profile →

Side-by-Side

AttributeAfamelanotideMelanotan II
Evidence GradeAC+
FDA StatusFDA-approved (2019) for erythropoietic protoporphyria (EPP)Not FDA-approved — sold illegally as cosmetic; FDA warning letters issued
Typical Dose16 mg subcutaneous implant every 2 months (clinical use)0.25–1 mg daily during loading, then maintenance (subcutaneous)
Clinics Indexed1418
Categoriesskinskin, sexual-health

Key reported benefits — Afamelanotide

  • MC1R-selective tanning
  • FDA-approved for EPP

Key reported benefits — Melanotan II

  • UV-independent tanning
  • Erectile effect (off-label)

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons